rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IHE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT? | The Motley Fool

      iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.

      Nov 11The Motley FoolFBTIHE
      Pharmaceuticals ETF (IHE) Hits a New 52-Week High
      Nov 11Yahoo FinanceIHE
      Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors | The Motley Fool

      IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.

      Nov 7The Motley FoolIBBIHE
      Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? | The Motley Fool

      IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.

      Oct 26The Motley FoolPPHDESKIHE
      Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now?

      Smart Beta ETF report for FTXH

      Oct 15Yahoo FinanceFTXHFTXLFTXOFTXRIHE
      Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
      Oct 12Yahoo FinanceIVZIHE
      Better Pharma ETF: iShares IHE vs. State Street XPH | The Motley Fool

      IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

      Oct 10The Motley FoolIHEXPH
      IHE: Innovation Supports The Outlook, Valuation Limits Conviction (NYSEARCA:IHE)
      Sep 11Seeking AlphaIHE
      IHE: Large-Cap Pharma Cools After A Hot Summer (NYSEARCA:IHE)

      Hold-rated iShares US Pharmaceuticals ETF: fair valuation, concentrated holdings, weak technicals, and seasonal headwinds. Learn more about the IHE ETF here.

      Sep 10Seeking AlphaIHE
      Does iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund? | The Motley Fool

      IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.

      Sep 8The Motley FoolIHERSPH
      Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

      IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

      Sep 8Yahoo FinanceIHE
      Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? | The Motley Fool

      IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

      Aug 21The Motley FoolIHE

      This is the newest page. Registered accounts read further back.